RESUMO
Skeletal muscle atrophy occurs in response to various pathophysiological stimuli, including disuse, aging, and neuromuscular disorders, mainly due to an imbalance of anabolic/catabolic signaling. Branched Chain Amino Acids (BCAAs: leucine, isoleucine, valine) supplements can be beneficial for counteracting muscle atrophy, in virtue of their reported anabolic properties. Here, we carried out a proof-of-concept study to assess the in vivo/ex vivo effects of a 4-week treatment with BCAAs on disuse-induced atrophy, in a murine model of hind limb unloading (HU). BCAAs were formulated in drinking water, alone, or plus two equivalents of L-Alanine (2 ALA) or the dipeptide L-Alanyl-L-Alanine (Di-ALA), to boost BCAAs bioavailability. HU mice were characterized by reduction of body mass, decrease of soleus - SOL - muscle mass and total protein, alteration of postural muscles architecture and fiber size, dysregulation of atrophy-related genes (Atrogin-1, MuRF-1, mTOR, Mstn). In parallel, we provided new robust readouts in the HU murine model, such as impaired in vivo isometric torque and ex vivo SOL muscle contractility and elasticity, as well as altered immune response. An acute pharmacokinetic study confirmed that L-ALA, also as dipeptide, enhanced plasma exposure of BCAAs. Globally, the most sensitive parameters to BCAAs action were muscle atrophy and myofiber cross-sectional area, muscle force and compliance to stress, protein synthesis via mTOR and innate immunity, with the new BCAAs + Di-ALA formulation being the most effective treatment. Our results support the working hypothesis and highlight the importance of developing innovative formulations to optimize BCAAs biodistribution.
Assuntos
Alanina/uso terapêutico , Aminoácidos de Cadeia Ramificada/uso terapêutico , Dipeptídeos/uso terapêutico , Atrofia Muscular/tratamento farmacológico , Alanina/farmacocinética , Aminoácidos de Cadeia Ramificada/farmacocinética , Animais , Dipeptídeos/farmacocinética , Modelos Animais de Doenças , Elevação dos Membros Posteriores , Masculino , Camundongos Endogâmicos C57BL , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/patologia , Músculo Esquelético/fisiologia , Atrofia Muscular/genética , Atrofia Muscular/patologia , Atrofia Muscular/fisiopatologia , Proteoma/efeitos dos fármacos , Transcriptoma/efeitos dos fármacosRESUMO
Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the pharmaceutical substance and tablet mass. GSB-106 concentrations in the blood plasma were determined by HPLC-mass spectrometry. Relative bioavailability of GSB-106 tablet form was 160.79±24.33%.
Assuntos
Antidepressivos/farmacocinética , Dipeptídeos/farmacocinética , Administração Oral , Animais , Antidepressivos/sangue , Área Sob a Curva , Disponibilidade Biológica , Dipeptídeos/sangue , Avaliação Pré-Clínica de Medicamentos , Masculino , Coelhos , ComprimidosRESUMO
Apart from nutrients required for the brain, there has been no report that naturally occurring peptides can cross the blood-brain barrier (BBB). The aim of this study was to identify the BBB-transportable peptides using in situ mouse perfusion experiments. Based on the structural features of Gly-N-methylated Gly (Gly-Sar), a reported BBB-transportable compound, 18 dipeptides were synthesized, and were perfused in the mouse brain for two minutes. Among the synthesized dipeptides, Gly-Sar, Gly-Pro, and Tyr-Pro were transported across the BBB with Ki values of 7.60 ± 1.29, 3.49 ± 0.66, and 3.53 ± 0.74 µL/g·min, respectively, and accumulated in the mouse brain parenchyma. Additionally, using MALDI-MS/MS imaging analysis of Tyr-Pro-perfused brain, we provide evidence for Tyr-Pro accumulation in the hippocampus, hypothalamus, striatum, cerebral cortex, and cerebellum of mouse brain.
Assuntos
Barreira Hematoencefálica/metabolismo , Dipeptídeos/farmacocinética , Animais , Cerebelo/metabolismo , Córtex Cerebral/metabolismo , Dipeptídeos/química , Hipocampo/metabolismo , Hipotálamo/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos ICR , Distribuição TecidualRESUMO
Decreased protein breakdown in pregnant women results in lower concentration of methionine (Met) in plasma, causing pregnancy-related metabolic disturbance. Its dipeptide methionyl-methionine (Met-Met) may exert positive influence in fetal development. This study mainly investigated whether Met-Met can be used as part of free Met to promote reproductive outcomes in mice and the underlying mechanisms. Met-deficient pregnant mice were treated with Met alone or with Met-Met during pregnancy. Daily intraperitoneal injection of 35% dietary Met in pregnant mice was the best dose among the 15â»45% doses. Embryo development and newborn birth weight were enhanced when 25% of the Met in the 35% Met group was replaced with Met-Met. Met-Met replacement had higher plasma insulin, glucose, and free amino acids (AA) concentrations. Besides, in the placenta, the AA transporter mRNA abundances and peptide transporters (PhT1 and PepT1) protein levels were higher in Met-Met treatment group. Moreover, Met-Met increased 4E-BP1, S6K1 and AKT/mTOR phosphorylation. These results suggest that Met-Met could be used as a partial source of Met to promote reproductive outcomes in Met-restricted pregnant mice, which might be mediated by promoting nutrient availability and activating AKT/mTOR-mediated signaling pathway.
Assuntos
Deficiências Nutricionais/tratamento farmacológico , Suplementos Nutricionais , Dipeptídeos/administração & dosagem , Metionina/administração & dosagem , Metionina/deficiência , Complicações na Gravidez/tratamento farmacológico , Reprodução/efeitos dos fármacos , Fenômenos Fisiológicos da Nutrição Animal , Animais , Biomarcadores/sangue , Deficiências Nutricionais/metabolismo , Deficiências Nutricionais/fisiopatologia , Dipeptídeos/farmacocinética , Modelos Animais de Doenças , Feminino , Desenvolvimento Fetal/efeitos dos fármacos , Injeções Intraperitoneais , Fenômenos Fisiológicos da Nutrição Materna , Proteínas de Membrana Transportadoras/metabolismo , Camundongos Endogâmicos ICR , Camundongos Nus , Estado Nutricional , Placenta/efeitos dos fármacos , Placenta/metabolismo , Gravidez , Complicações na Gravidez/metabolismo , Complicações na Gravidez/fisiopatologia , Transdução de Sinais/efeitos dos fármacosRESUMO
PURPOSE: Our purpose was to assess the amino acids' (AAs) profile in trauma patients and to assess the effect of the route of nutrition and the exogenous ALA-GLN dipeptide supplementation on plasma AAs' concentration. METHODS: This is a secondary analysis of a previous randomized controlled trial. On day 1 and day 6 after trauma, plasma concentration of 25 AAs was measured using reverse phase high-performance liquid chromatography. Results were analyzed in relation to the route of nutrition and supplementation of ALA-GLN dipeptide. Differences between plasma AAs' concentrations at day 1 and day 6 were evaluated using the Student's t test or Mann-Whitney-Wilcoxon test. One-way ANOVA and the Kruskal-Wallis test were used to compare groups. A two-sided p value less than 0.05 was considered statistically significant. RESULTS: Ninety-eight patients were analyzed. Mean plasma concentrations at day 1 were close to the lower normal level for most AAs. At day 6 we found an increase in the eight essential AAs' concentrations and in 9 out of 17 measured non-essential AAs. At day 6 we found no differences in plasma concentrations for the sum of all AAs (p = .72), glutamine (p = .31) and arginine (p = .23) distributed by the route of nutrition. Administration of ALA-GLN dipeptide increased the plasma concentration of alanine (p = .004), glutamine (p < .001) and citrulline (p = .006). CONCLUSIONS: We found an early depletion of plasma AAs' concentration which partially recovered at day 6, which was unaffected by the route of nutrition. ALA-GLN dipeptide supplementation produced a small increase in plasma levels of glutamine and citrulline.
Assuntos
Aminoácidos/metabolismo , Suplementos Nutricionais , Dipeptídeos/administração & dosagem , Ferimentos e Lesões/metabolismo , Adolescente , Adulto , Idoso , Aminoácidos/sangue , Dipeptídeos/farmacocinética , Nutrição Enteral , Feminino , Humanos , Escala de Gravidade do Ferimento , Masculino , Pessoa de Meia-Idade , Estado Nutricional , Nutrição Parenteral , Resultado do Tratamento , Ferimentos e Lesões/sangue , Adulto JovemRESUMO
Food supplementation with the conditionally essential amino acid arginine (Arg) has been shown to have nutritional benefits. Degradation of cyanophycin (CGP), a peptide polymer used for nitrogen storage by cyanobacteria, requires cyanophycinase (CGPase) and results in the release of ß-aspartic acid (Asp)-Arg dipeptides. The simultaneous production of CGP and CGPase in plants could be a convenient source of Arg dipeptides. Different variants of the cphB coding region from Thermosynechococcus elongatus BP-1 were transiently expressed in Nicotiana benthamiana plants. Translation and enzyme stability were optimized to produce high amounts of active CGPase. Protein stability was increased by the translational fusion of CGPase to the green fluorescent protein (GFP) or to the transit peptide of the small subunit of RuBisCO for peptide production in the chloroplasts. Studies in mice showed that plant-expressed CGP fed in combination with plant-made CGPase was hydrolysed in the intestine, and high levels of ß-Asp-Arg dipeptides were found in plasma, demonstrating dipeptide absorption. However, the lack of an increase in Asp and Arg or its metabolite ornithine in plasma suggests that Arg from CGP was not bioavailable in this mouse group. Intestinal degradation of CGP by CGPase led to low intestinal CGP content 4 h after consumption, but after ingestion of CGP alone, high CGP concentrations remained in the large intestine; this indicated that intact CGP was transported from the small to the large intestine and that CGP was resistant to colonic microbes.
Assuntos
Proteínas de Bactérias/metabolismo , Mucosa Intestinal/metabolismo , Nicotiana/metabolismo , Peptídeo Hidrolases/genética , Peptídeo Hidrolases/metabolismo , Animais , Arginina/farmacocinética , Disponibilidade Biológica , Cloroplastos/genética , Cloroplastos/metabolismo , Citosol/metabolismo , Suplementos Nutricionais , Dipeptídeos/farmacocinética , Hidrólise , Masculino , Camundongos , Extratos Vegetais/química , Plantas Geneticamente Modificadas , Nicotiana/genéticaRESUMO
BACKGROUND: Peritonitis and ultrafiltration failure remain serious complications of chronic peritoneal dialysis (PD). Dysfunctional cellular stress responses aggravate peritoneal injury associated with PD fluid exposure, potentially due to peritoneal glutamine depletion. In this randomized cross-over phase I/II trial we investigated cytoprotective effects of alanyl-glutamine (AlaGln) addition to glucose-based PDF. METHODS: In a prospective randomized cross-over design, 20 stable PD outpatients underwent paired peritoneal equilibration tests 4 weeks apart, using conventional acidic, single chamber 3.86% glucose PD fluid, with and without 8 mM supplemental AlaGln. Heat-shock protein 72 expression was assessed in peritoneal effluent cells as surrogate parameter of cellular stress responses, complemented by metabolomics and functional immunocompetence assays. RESULTS: AlaGln restored peritoneal glutamine levels and increased the primary outcome heat-shock protein expression (effect 1.51-fold, CI 1.07-2.14; p = 0.022), without changes in peritoneal ultrafiltration, small solute transport, or biomarkers reflecting cell mass and inflammation. Further effects were glutamine-like metabolomic changes and increased ex-vivo LPS-stimulated cytokine release from healthy donor peripheral blood monocytes. In patients with a history of peritonitis (5 of 20), AlaGln supplementation decreased dialysate interleukin-8 levels. Supplemented PD fluid also attenuated inflammation and enhanced stimulated cytokine release in a mouse model of PD-associated peritonitis. CONCLUSION: We conclude that AlaGln-supplemented, glucose-based PD fluid can restore peritoneal cellular stress responses with attenuation of sterile inflammation, and may improve peritoneal host-defense in the setting of PD.
Assuntos
Soluções para Diálise , Dipeptídeos/farmacologia , Estresse Fisiológico , Idoso , Estudos Cross-Over , Dipeptídeos/farmacocinética , Eletroforese em Gel Bidimensional , Feminino , Proteínas de Choque Térmico/metabolismo , Humanos , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
Aurantiamide and aurantiamide acetate are the main active constituents of purslane (Portulaca oleracea L.), an edible plant with various biological activities. In this study, we developed a validated UHPLC-MS/MS method to quantitate the concentrations of aurantiamide and aurantiamide acetate in the plasma and various organ tissues of rat as the basis to study their pharmacological profile and distribution in vivo. Aurantiamide and aurantiamide acetate were rapidly absorbed following oral administration, both achieving a Cmax at around 0.2 h. The extent of their metabolisms also varied among different organ tissues, resulting in about 90% reduction in concentrations 4 h after their administration, thus leaving no long-term accumulation in the tissues. This is the first study to examine the pharmacokinetic and biodistribution of aurantiamide and aurantiamide acetate in rat, and our work may serve as the first step toward the investigation of the underlying mechanisms associated with the biological activity of purslane.
Assuntos
Dipeptídeos/farmacocinética , Extratos Vegetais/administração & dosagem , Extratos Vegetais/farmacocinética , Portulaca/química , Administração Oral , Animais , Masculino , Ratos , Ratos Sprague-Dawley , Distribuição TecidualRESUMO
We evaluated the effects of the supplementation with L-glutamine and glutamine dipeptide (GDP) on biochemical and morphophysiological parameters in streptozotocin-diabetic rats. For this purpose, thirty animals were distributed into six groups treated orally (gavage) during thirty days: non diabetic rats (Control) + saline, diabetic + saline; Control + L-glutamine (248 mg/kg), Diabetic + L-glutamine (248 mg/kg), Control + GDP (400 mg/kg), Diabetic + GDP (400 mg/kg). Diabetes was induced by an intravenous injection of streptozotocin (60 mg/kg) and confirmed by fasting glucose ≥ 200 mg/dL. Physiological parameters, i.e., body mass, food intake, blood glucose, water intake, urine and faeces were evaluated during supplementation. After the period of supplementation, the animals were euthanized. The blood was collected for biochemical assays (fructosamine, transaminases, lipid profile, total protein, urea, ammonia). Moreover, the jejunum was excised and stored for morphophysiological assays (intestinal enzyme activity, intestinal wall morphology, crypt proliferative index, number of serotoninergic cells from the mucosa, and vipergic neurons from the submucosal tunica). The physiological parameters, protein metabolism and intestinal enzyme activity did not change with the supplementation with L-glutamine or GDP. In diabetic animals, transaminases and fructosamine improved with L-glutamine and GDP supplementations, while the lipid profile improved with L-glutamine. Furthermore, both forms of supplementation promoted changes in jejunal tunicas and wall morphometry of control and diabetic groups, but only L-glutamine promoted maintenance of serotoninergic cells and vipergic neurons populations. On the other hand, control animals showed changes that may indicate negative effects of L-glutamine. Thus, the supplementation with L-glutamine was more efficient for maintaining intestinal morphophysiology and the supplementation with GDP was more efficient to the organism as a whole. Thus, we can conclude that local differences in absorption and metabolism could explain the differences between the supplementation with L-glutamine or GDP.
Assuntos
Diabetes Mellitus Experimental/tratamento farmacológico , Dipeptídeos/farmacologia , Glutamina/farmacologia , Jejuno/efeitos dos fármacos , Animais , Glicemia/metabolismo , Diabetes Mellitus Experimental/sangue , Diabetes Mellitus Experimental/metabolismo , Suplementos Nutricionais , Dipeptídeos/farmacocinética , Glutamina/farmacocinética , Absorção Intestinal/efeitos dos fármacos , Jejuno/metabolismo , Jejuno/fisiopatologia , Masculino , Ratos , Ratos WistarRESUMO
PURPOSE: We have previously shown favorable in vitro gut permeability for three novel di-peptide esters of glucosamine (GlcN) likely facilitated by the peptide transporter 1 (PepT1). Herein, we report the development of a novel assay for the determination of bioavailability of the peptide ester of interest, the anti-inflammatory properties of a glycine-valine ester derivative of GlcN (GVG) as well as its pharmacokinetics under healthy and inflammatory conditions. METHODS: A pre-column derivatization (with 9-fluorenylmethoxycarbonyl) HPLC assay was developed to study bioavailability of GVG, GlcN or cleaved GlcN in the rats that were cannulated in their right jugular vein for blood collection. The compounds of interest were orally administered to both healthy and arthritic rats. Serial blood samples and urine were collected and assayed for the compounds. The stability of the GVG was also tested after incubation with the rat feces. Efficacy of GVG was tested in inflamed rats (injection of 0.2 mL of Mycobacterium butyricum in squalene) following GVG (20 and 30 mg/kg/day GlcN equivalent) or GlcN (20 and 90 mg/kg/day) administration. Arthritis index was calculated at the end of the experiment. RESULTS: The assay was linear (ranged between 0.05-20 µg/mL) and reproducible (intra- and inter-day<10%). Among the tested compounds, only GVG showed a significantly higher plasma concentrations and urinary excretion than GlcN (≈3-fold increase). GVG showed a favorable stability in the rat feces. Adjuvant arthritis was completely prevented with doses greater than 20 mg/kg/day with GVG being 3-fold more potent than GlcN. CONCLUSION: The examined glycine-valine-GlcN di-peptide aminosugar is a potent anti-inflammatory compound due to its favorable properties to deliver GlcN into the systemic circulation.
Assuntos
Anti-Inflamatórios/farmacocinética , Artrite Experimental/metabolismo , Dipeptídeos/farmacocinética , Glucosamina/análogos & derivados , Glucosamina/farmacocinética , Animais , Anti-Inflamatórios/uso terapêutico , Artrite Experimental/tratamento farmacológico , Disponibilidade Biológica , Dipeptídeos/uso terapêutico , Ésteres , Fezes/química , Glucosamina/uso terapêutico , Masculino , Ratos , Ratos Sprague-DawleyRESUMO
ETHNOPHARMACOLOGICAL RELEVANCE: Cooked rhubarb and wine processed rhubarb are the processed rhubarbs of raw rhizomes from Rheum palmatum L., Rheum tanguticum Maxim. ex Balf. or Rheum officinale Baill. They are clinically used in traditional Chinese medicine to compose anti-diabetic formulas and remove pathogenic heat or toxin from the body. AIM OF THE STUDY: To elucidate potential influences processed rhubarbs might have on the activities of four cytochrome P450 (CYP) isozyme in rats (CYP1A2, CYP2C6, CYP2E1, and CYP3A1) and on the pharmacokinetics of saxagliptin. MATERIALS AND METHODS: Relative activity estimation of four isozymes or influence on saxagliptin was carried out by comparing plasma pharmacokinetics of four respective substrates (theophylline for CYP1A2, tolbutamide for CYP2C6, chlorzoxazone for CYP2E1, and dapsone for CYP3A1) or saxagliptin between control and processed rhubarbs pretreated groups. Plasma concentrations of substrates and saxagliptin were quantified using UPLC-UV and UPLC-MS/MS methods, respectively. RESULTS: Wine processed rhubarb induced CYP1A2 activity; both the processed rhubarbs inhibited the CYP2C6 activity and induced CYP2E1; cooked rhubarb induced CYP3A1 activity. Both the processed rhubarbs reduced the absorbance and bioavailability, but increased the clearance of saxagliptin. CONCLUSIONS: Processed rhubarbs can either induce or inhibit activities of CYP1A2, CYP2C6, CYP2E1, and CYP3A1, and modify the metabolism of saxagliptin. The results indicated that drug co-administrated with processed rhubarbs may need dose adjustment.
Assuntos
Adamantano/análogos & derivados , Sistema Enzimático do Citocromo P-450/metabolismo , Dipeptídeos/farmacocinética , Inibidores da Dipeptidil Peptidase IV/farmacocinética , Extratos Vegetais/farmacologia , Rheum , Adamantano/farmacocinética , Animais , Clorzoxazona/farmacocinética , Dapsona/farmacocinética , Ativadores de Enzimas/farmacologia , Inibidores Enzimáticos/farmacologia , Interações Ervas-Drogas , Isoenzimas/metabolismo , Masculino , Ratos , Ratos Wistar , Teofilina/farmacocinética , Tolbutamida/farmacocinética , VinhoRESUMO
A simple, accurate and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method was developed and validated for quantitation of bentysrepinine (Y101) in rat plasma. After the addition of diphenhydramine (internal standard, IS), plasma samples were pretreated by protein precipitation. Chromatographic separation was carried out on an Atlantis(®) analytical column (4.6 mm × 100 mm, 5 µm, Waters) with methanol: 20 mM ammonium formate consisting of 1.0% formic acid (65:35, v/v) as the mobile phase at an isocratic flow rate of 0.4 mL/min for 7.5 min. The multiple reaction monitoring (MRM) transitions were performed at m/z 490.2â339.5 for Y101 and m/z 256.0â167.0 for IS on a SCIEX API 4000 mass spectrometer in the positive ion mode with electrospray ionization (ESI) source. Good linearity was achieved over the concentration range of 1-2500 ng/mL. The intra- and inter-day precisions were less than 8.3%, and the accuracy ranged from -4.0% to 2.8%. Y101 was stable during the analysis and the storage period. The pharmacokinetic profiles of Y101 at three dose levels were successfully studied for the first time in rats by this method. After single intra-gastric administration of Y101 at the doses of 25, 50 and 100 mg/kg, C(max) and AUC(0-t) were proportional to the doses given.
Assuntos
Antivirais/sangue , Benzamidas/sangue , Cromatografia Líquida/métodos , Dipeptídeos/sangue , Extratos Vegetais/sangue , Espectrometria de Massas em Tandem/métodos , Animais , Antivirais/química , Antivirais/farmacocinética , Benzamidas/química , Benzamidas/farmacocinética , Dipeptídeos/química , Dipeptídeos/farmacocinética , Estabilidade de Medicamentos , Masculino , Extratos Vegetais/química , Extratos Vegetais/farmacocinética , Ratos , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
INTRODUCTION: LK-423 is a new phthalimido-desmuramyl-dipeptide derivative with immunomodulating activity. As optimized delivery to the site of action appears crucial for further preclinical development of LK-423, the aim of this study was to perform a physicochemical and preclinical pharmacokinetic and toxicological evaluation. METHODS: The solubility, partition coefficient, permeability, and stability profile were determined. Pharmacokinetics were evaluated in rats following intravenous and oral application of LK-423, and in dogs after intravenous administration and oral administration of microcapsules, designed for colon-specific delivery of LK-423 based on pH-, time-, and enzyme-controlled release mechanisms. Additionally, the acute and subchronic toxicity was examined. RESULTS AND DISCUSSION: LK-423 is hydrophilic, sparingly to slightly soluble, and poorly permeable. Stability profile in aqueous solution is pH dependent. A pharmacokinetic study following intravenous application to rats and dogs revealed that LK-423 is rapidly eliminated with a short terminal phase half-life, and high plasma clearance, as well as a limited distribution to the peripheral tissue. Oral bioavailability of LK-423 is low, presumably due to low permeability. Debris of insoluble microcapsule coating in feces and obtained plasma concentration profiles confirm that LK-423 microcapsules are a promising approach for local treatment of inflammatory diseases of the large intestine. Acute and a subchronic toxicity results indicate that LK-423 is a safe and nontoxic drug under the applied experimental conditions.
Assuntos
Dipeptídeos/química , Dipeptídeos/farmacocinética , Dipeptídeos/toxicidade , Fatores Imunológicos/química , Fatores Imunológicos/farmacocinética , Fatores Imunológicos/toxicidade , Ftalimidas/química , Ftalimidas/farmacocinética , Ftalimidas/toxicidade , Administração Oral , Animais , Cápsulas , Cromatografia Líquida de Alta Pressão , Preparações de Ação Retardada , Dipeptídeos/administração & dosagem , Dipeptídeos/sangue , Cães , Avaliação Pré-Clínica de Medicamentos/métodos , Estabilidade de Medicamentos , Concentração de Íons de Hidrogênio , Fatores Imunológicos/administração & dosagem , Fatores Imunológicos/sangue , Injeções Intraperitoneais , Injeções Intravenosas , Absorção Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Masculino , Espectrometria de Massas , Camundongos , Camundongos Endogâmicos , Estrutura Molecular , Ftalimidas/administração & dosagem , Ftalimidas/sangue , Ratos , Ratos Wistar , Solubilidade , Testes de Toxicidade Aguda , Testes de Toxicidade CrônicaRESUMO
BACKGROUND: We sought to investigate the effect of IV alanyl-glutamine supplementation on plasma glutathione levels in severely traumatized patients receiving enteral nutrition. METHODS: Forty adult patients with severe trauma according to the Injury Severity Score >20 were enrolled in this randomized, controlled study. The patients were assigned to two groups: Group G received 0.5 g x kg(-1) x d(-1) of alanyl-glutamine dipeptide supplementation IV, and Group C received a control solution without alanyl-glutamine for 7 days. Blood samples were taken for analysis of glutathione before the initiation of supplementation and on the 3rd, 7th, and 10th days of feeding. RESULTS: Total plasma glutathione levels significantly increased in Group G when compared with Group C on Days 7 and 10 (1.34 +/- 0.20 microM vs 1.13 +/- 0.14 microM, and 1.38 +/- 0.19 microM vs 1.12 +/- 0.16 microM) (P < 0.001). CONCLUSIONS: This study demonstrates that IV alanyl-glutamine supplementation for 7 days increases total plasma glutathione levels in critically ill trauma patients receiving standard enteral nutrition.
Assuntos
Dipeptídeos/farmacocinética , Nutrição Enteral , Glutationa/sangue , Ferimentos e Lesões/sangue , Adolescente , Adulto , Idoso , Cuidados Críticos , Estado Terminal , Infecção Hospitalar/epidemiologia , Feminino , Humanos , Unidades de Terapia Intensiva , Masculino , Pessoa de Meia-Idade , Ferimentos e Lesões/terapia , Adulto JovemRESUMO
Saxagliptin is a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing. Saxagliptin is metabolized in vivo to form an active metabolite, and both parent drug and metabolite are excreted primarily via the kidneys. Saxagliptin reduces the degradation of the incretin hormone glucagon-like peptide-1, thereby enhancing its actions, and is associated with improved beta-cell function and suppression of glucagon secretion. Clinical trials of up to 24 weeks duration have shown that saxagliptin improves glycemic control in monotherapy and provides additional efficacy when used in combination with other oral antidiabetic agents (metformin, sulfonylurea, thiazolidinedione). Both fasting and postprandial glucose concentrations are reduce leading to clinically meaningful reductions in glycated hemoglobin, and due to the glucose-dependency of its mechanism of action, there is a low risk of hypoglycemia. Saxagliptin is reported to be well tolerated with a side-effect profile similar to placebo. It has a neutral effect on body weight and dose adjustment because of age, gender, or hepatic impairment is not necessary. Saxagliptin is being co-developed by Bristol-Myers-Squibb (New York, NY, USA) and AstraZeneca (Cheshire, UK), and is currently undergoing regulatory review.
Assuntos
Adamantano/análogos & derivados , Diabetes Mellitus Tipo 2/tratamento farmacológico , Dipeptídeos/uso terapêutico , Inibidores da Dipeptidil Peptidase IV/uso terapêutico , Adamantano/química , Adamantano/metabolismo , Adamantano/farmacocinética , Adamantano/uso terapêutico , Administração Oral , Glicemia/efeitos dos fármacos , Ensaios Clínicos como Assunto , Diabetes Mellitus Tipo 2/metabolismo , Dipeptídeos/química , Dipeptídeos/metabolismo , Dipeptídeos/farmacocinética , Inibidores da Dipeptidil Peptidase IV/química , Inibidores da Dipeptidil Peptidase IV/metabolismo , Inibidores da Dipeptidil Peptidase IV/farmacocinética , Esquema de Medicação , Avaliação Pré-Clínica de Medicamentos , Quimioterapia Combinada , Peptídeo 1 Semelhante ao Glucagon/efeitos dos fármacos , Humanos , Hipoglicemia/induzido quimicamente , Segurança , Resultado do TratamentoRESUMO
Saxagliptin is a potent, selective, reversible dipeptidyl peptidase 4 (DPP4) inhibitor specifically designed for extended inhibition of the DPP4 enzyme and is currently under development for the treatment of type-2 diabetes. The pharmacokinetics of saxagliptin were evaluated in rats, dogs, and monkeys and used to predict its human pharmacokinetics. Saxagliptin was rapidly absorbed and had good bioavailability (50-75%) in the species tested. The plasma clearance of saxagliptin was higher in rats (115 ml/min/kg) than in dogs (9.3 ml/min/kg) and monkeys (14.5 ml/min/kg) and was predicted to be low to moderate in humans. The plasma elimination half-life was between 2.1 and 4.4 h in rats, dogs, and monkeys, and both metabolism and renal excretion contributed to the overall elimination. The primary metabolic clearance pathway involved the formation of a significant circulating, pharmacologically active hydroxylated metabolite, M2. The volume of distribution values observed in rats, dogs, and monkeys (1.3-5.2 l/kg) and predicted for humans (2.7 l/kg) were greater than those for total body water, indicating extravascular distribution. The in vitro serum protein binding was low (< or =30%) in rats, dogs, monkeys, and humans. After intra-arterial administration of saxagliptin to Sprague-Dawley and Zucker diabetic fatty rats, higher levels of saxagliptin and M2 were observed in the intestine (a proposed major site of drug action) relative to that in plasma. Saxagliptin has prolonged pharmacodynamic properties relative to its plasma pharmacokinetic profile, presumably due to additional contributions from M2, distribution of saxagliptin and M2 to the intestinal tissue, and prolonged dissociation of both saxagliptin and M2 from DPP4.
Assuntos
Adamantano/análogos & derivados , Dipeptídeos/farmacocinética , Inibidores da Dipeptidil Peptidase IV/farmacocinética , Taxa de Depuração Metabólica , Microssomos Hepáticos/metabolismo , Especificidade da Espécie , Adamantano/farmacocinética , Animais , Disponibilidade Biológica , Cães , Avaliação Pré-Clínica de Medicamentos , Meia-Vida , Haplorrinos , Humanos , Ligação Proteica , Ratos , Ratos Sprague-Dawley , Ratos ZuckerRESUMO
BACKGROUND & AIMS: Exogenous intravenous glutamine supplementation to head trauma patients leaves intracerebral glutamate concentration unaffected. The effect of an exogenous supply upon glutamine and glutamate exchange across the brain has still not been characterised. METHODS: A prospective randomised cross-over study, where i.v. glutamine dipeptide was compared with placebo. Arterio-venous concentration differences of free amino acids across the brain and amino acid flux across the leg were measured. In addition, the endogenous glutamine production was calculated. Fifteen mechanically ventilated head trauma patients with GCS < or =8 were included and studied during two consecutive 24-h periods on days 2-5 following head trauma. RESULTS: Glutamine was continuously released from both the brain and the leg. The arterio-venous (a-v) concentration differences over the brain were calculated to be -49+/-26 and -27+/-14 micromol/L during the treatment and control periods respectively, showing a continuous release of glutamine (p<0.0001). On the other hand, the a-v difference of glutamate was not different from zero (p>0.2). The whole-body glutamine rate of appearance (R(a)) was calculated to be 218+/-75micromol/kg body weight/h. CONCLUSION: Intravenous glutamine supplementation to head trauma patients was associated with an unaffected amino acid exchange pattern across head and leg, without any measurable uptake of glutamate across the brain. Endogenous glutamine production was in the normal range despite the low plasma glutamine concentration. This pilot study opens the possibility to perform prospective clinical trials in head trauma patients to evaluate the clinical efficacy of exogenous glutamine supplementation.
Assuntos
Encéfalo/metabolismo , Traumatismos Craniocerebrais/metabolismo , Ácido Glutâmico/metabolismo , Glutamina/administração & dosagem , Glutamina/metabolismo , Adolescente , Adulto , Idoso , Estudos Transversais , Dipeptídeos/administração & dosagem , Dipeptídeos/farmacocinética , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Nutrição Parenteral , Projetos Piloto , Estudos Prospectivos , Adulto JovemRESUMO
3-(S)-1,2,3,4-Tetrahydro-beta-carboline-3-carboxylic acid isolated from A. Chinese G. Don was found to possess moderate anti-aggregation activity, but with poor bioavailability. To improve its pharmacological property, we designed and synthesized a series of novel dipeptide analogues by incorporating tetrahydro-beta-carboline-3-carboxylic acid skeleton as an amino acid surrogate (*Trp). It turned out these dipeptide analogues exhibited good membrane permeability based on in vitro Caco-2 cell monolayers permeability assay. As a result, the overall biological properties of these molecules were significantly improved depending on the nature of the amino acid residues introduced onto the 3-position of the tetrahydro-beta-carboline moiety. It was very interesting to notice that these dipeptide analogues (5b,c,h,i,n,o,p,q) displayed a remarkable dual antiaggregatory activity in both of ADP- and PAF-induced platelet aggregation assay, and their aggregation response was significantly higher than that of aspirin (p<0.01). In addition, these dipeptide analogues were observed for the dose-dependent antithrombotic effect using in vivo rat arterial thrombosis model. The potency of antithrombotic activity of 5h,i,n,p was significantly higher than that of aspirin (n=12, p<0.01) at equal dose (5 micromol/kg).
Assuntos
Dipeptídeos/síntese química , Dipeptídeos/farmacologia , Fibrinolíticos/síntese química , Fibrinolíticos/farmacologia , Animais , Aspirina/farmacologia , Disponibilidade Biológica , Células CACO-2 , Dipeptídeos/química , Dipeptídeos/farmacocinética , Avaliação Pré-Clínica de Medicamentos , Fibrinolíticos/química , Fibrinolíticos/farmacocinética , Humanos , Técnicas In Vitro , Masculino , Permeabilidade , Agregação Plaquetária/efeitos dos fármacos , Coelhos , Ratos , Ratos WistarRESUMO
Beta-alanine in blood-plasma when administered as A) histidine dipeptides (equivalent to 40 mg . kg(-1) bwt of beta-alanine) in chicken broth, or B) 10, C) 20 and D) 40 mg . kg(-1) bwt beta-alanine (CarnoSyn, NAI, USA), peaked at 428 +/- SE 66, 47 +/- 13, 374 +/- 68 and 833 +/- 43 microM. Concentrations regained baseline at 2 h. Carnosine was not detected in plasma with A) although traces of this and anserine were found in urine. Loss of beta-alanine in urine with B) to D) was <5%. Plasma taurine was increased by beta-alanine ingestion but this did not result in any increased loss via urine. Pharmacodynamics were further investigated with 3 x B) per day given for 15 d. Dietary supplementation with I) 3.2 and II) 6.4 g . d(-1) beta-alanine (as multiple doses of 400 or 800 mg) or III) L-carnosine (isomolar to II) for 4 w resulted in significant increases in muscle carnosine estimated at 42.1, 64.2 and 65.8%.
Assuntos
Carnosina/metabolismo , Suplementos Nutricionais , Músculo Quadríceps/metabolismo , beta-Alanina/farmacocinética , Adulto , Idoso , Idoso de 80 Anos ou mais , Dipeptídeos/administração & dosagem , Dipeptídeos/farmacocinética , Humanos , Masculino , Taurina/sangue , Taurina/urina , beta-Alanina/administração & dosagemRESUMO
SciClone Pharmaceuticals and Verta are developing SCV-07, the lead in a series of immnunostimulants from Verta, for the potential treatment of tuberculosis and hepatitis C virus infection. Phase II clinical trials of the compound are ongoing.